Osaka Medical and Pharmaceutical University Submits Clinical Trial Notification for Phase III Investigator-Initiated Trial Targeting Recurrent Glioblastoma Using Our BNCT System

AI Summary (NQ-processed)

Osaka Medical and Pharmaceutical University, a client of Sumitomo Heavy Industries' BNCT treatment system, has submitted a clinical trial notification for a Phase III investigator-initiated trial for recurrent glioblastoma. This trial will use our BNCT equipment and a boron agent from Stella Pharma Corporation to establish a new treatment option. We will cooperate with the university to ensure the smooth implementation of the trial.